Clinical Trial Update: Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the maintenance of efficacy of Risperidone Long Acting Injectable (R-LAI) in schizophrenia or schizoaffective disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Risperdal Consta (risperidone long-acting injectable)

Snippet

Sponsor: Janssen-Cilag S.p.A. | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 3 | Status: COMPLETED